Prestige Consumer Healthcare (NYSE:PBH) Price Target Raised to $100.00

Prestige Consumer Healthcare (NYSE:PBH) had its price objective upped by Canaccord Genuity Group from $93.00 to $100.00 in a report issued on Friday morning,Benzinga reports. They currently have a buy rating on the stock.

Other research analysts have also recently issued research reports about the stock. DA Davidson boosted their price target on shares of Prestige Consumer Healthcare from $95.00 to $104.00 and gave the stock a “buy” rating in a report on Friday. Raymond James raised shares of Prestige Consumer Healthcare to a “moderate buy” rating in a research report on Thursday, December 19th. StockNews.com raised Prestige Consumer Healthcare from a “hold” rating to a “buy” rating in a report on Friday, January 24th. Finally, Sidoti downgraded Prestige Consumer Healthcare from a “buy” rating to a “neutral” rating and set a $90.00 price target for the company. in a report on Monday, December 9th. Two research analysts have rated the stock with a hold rating and three have issued a buy rating to the company. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $92.50.

Prestige Consumer Healthcare Stock Down 0.4 %

Shares of NYSE PBH opened at $86.96 on Friday. Prestige Consumer Healthcare has a 12-month low of $60.00 and a 12-month high of $88.36. The stock has a market cap of $4.30 billion, a P/E ratio of 20.37, a PEG ratio of 2.43 and a beta of 0.50. The company has a current ratio of 3.68, a quick ratio of 2.10 and a debt-to-equity ratio of 0.56. The business’s fifty day simple moving average is $79.23 and its 200-day simple moving average is $75.48.

Prestige Consumer Healthcare (NYSE:PBH) last announced its quarterly earnings data on Thursday, February 6th. The company reported $1.22 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.18 by $0.04. Prestige Consumer Healthcare had a return on equity of 12.36% and a net margin of 19.13%. As a group, equities analysts predict that Prestige Consumer Healthcare will post 4.5 EPS for the current fiscal year.

Insider Buying and Selling

In related news, EVP Adel Mekhail sold 9,063 shares of the firm’s stock in a transaction that occurred on Tuesday, November 12th. The stock was sold at an average price of $82.00, for a total transaction of $743,166.00. Following the transaction, the executive vice president now owns 18,365 shares in the company, valued at $1,505,930. This trade represents a 33.04 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Also, insider William P’pool sold 8,987 shares of the business’s stock in a transaction that occurred on Tuesday, November 12th. The shares were sold at an average price of $81.85, for a total value of $735,585.95. Following the completion of the sale, the insider now owns 20,058 shares of the company’s stock, valued at approximately $1,641,747.30. This represents a 30.94 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 38,810 shares of company stock worth $3,187,300 in the last ninety days. 1.60% of the stock is owned by corporate insiders.

Institutional Trading of Prestige Consumer Healthcare

A number of large investors have recently bought and sold shares of the business. Kestra Investment Management LLC purchased a new stake in shares of Prestige Consumer Healthcare in the fourth quarter valued at about $27,000. Northwestern Mutual Wealth Management Co. increased its position in Prestige Consumer Healthcare by 562.3% in the 2nd quarter. Northwestern Mutual Wealth Management Co. now owns 510 shares of the company’s stock valued at $35,000 after acquiring an additional 433 shares during the period. nVerses Capital LLC raised its stake in Prestige Consumer Healthcare by 200.0% during the 3rd quarter. nVerses Capital LLC now owns 600 shares of the company’s stock valued at $43,000 after acquiring an additional 400 shares during the last quarter. Huntington National Bank lifted its position in Prestige Consumer Healthcare by 39.9% during the 3rd quarter. Huntington National Bank now owns 635 shares of the company’s stock worth $46,000 after acquiring an additional 181 shares during the period. Finally, International Assets Investment Management LLC grew its stake in shares of Prestige Consumer Healthcare by 7,112.5% in the 3rd quarter. International Assets Investment Management LLC now owns 1,154 shares of the company’s stock valued at $83,000 after purchasing an additional 1,138 shares during the last quarter. Institutional investors and hedge funds own 99.95% of the company’s stock.

Prestige Consumer Healthcare Company Profile

Prestige Consumer Healthcare Inc, together with its subsidiaries, develops, manufactures, markets, distributes, and sells over-the-counter (OTC) health and personal care products in the United States and internationally. The company operates in two segments, North American OTC Healthcare and International OTC Healthcare.